Comprehensive Geriatric Assessment in Adults Aged 40 Years and Older Living With HIV

Prospective Comparative Evaluation of Frailty, Sarcopenia, Nutritional Status, Cognitive Function, and Functional Performance in Adults Aged 40 Years and Older Living With HIV and Age- and Sex-Matched Healthy Controls

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07453303

Acronym

HIV-AGE40

Enrollment

Registered

2026-03-05

Start date

2026-03-02

Completion date

2026-04-20

Last updated

2026-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Frailty, Sarcopenia

Keywords

HIV Infections

Brief summary

People living with HIV are experiencing longer life expectancy due to effective antiretroviral therapy; however, they may develop age-related conditions earlier than the general population. This prospective observational study aims to evaluate frailty, sarcopenia, nutritional status, cognitive function, and functional performance in adults aged 40 years and older living with HIV and to compare them with age- and sex-matched healthy controls.

Detailed description

With the widespread use of antiretroviral therapy, individuals living with HIV have achieved near-normal life expectancy. However, emerging evidence suggests that chronic inflammation, immune activation, and long-term treatment exposure may contribute to accelerated or premature aging processes. Frailty, sarcopenia, cognitive decline, and functional impairment have been increasingly reported in middle-aged and older adults living with HIV. This prospective observational cohort study aims to perform a comprehensive geriatric assessment in adults aged 40 years and older living with HIV and to compare the findings with age- and sex-matched healthy controls. The assessment will include evaluation of frailty, sarcopenia, nutritional status, cognitive function, and functional performance using standardized clinical tools. The primary objective is to determine the prevalence and characteristics of geriatric vulnerabilities in adults aged ≥40 years living with HIV. Secondary objectives include identifying factors associated with frailty and functional impairment in this population.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

40 Years to 99 Years

Healthy volunteers

Yes

Inclusion criteria

Age ≥ 40 years Confirmed diagnosis of HIV infection (for HIV group) On stable antiretroviral therapy for at least 6 months (for HIV group) HIV-negative status confirmed by medical history or testing (for control group) Ability to provide informed consent

Exclusion criteria

Acute infection or hospitalization within the last 4 weeks Known active malignancy under treatment Severe psychiatric disorder interfering with assessment Severe cognitive impairment preventing participation

Design outcomes

Primary

Measure	Time frame	Description
Prevalence of Frailty	Baseline	Frailty status assessed using a validated frailty assessment tool and defined according to established criteria in adults aged 40 years and older living with HIV and age- and sex-matched healthy controls.

Outcome results